Results 21 to 30 of about 8,252,790 (324)

Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy

open access: yesEuropean Journal of Health Economics, 2023
Over the past decades, US Congress enabled the US Food and Drug Administration (FDA) to facilitate and expedite drug development for serious conditions filling unmet medical needs with five special designations and review pathways: orphan, fast track ...
D. Michaeli   +4 more
semanticscholar   +1 more source

Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development

open access: yesThe Lancet Regional Health - Americas, 2023
Summary In 2021, the US Food and Drug Administration (FDA) granted approval to aducanumab, an antiamyloid antibody for early-stage Alzheimer's disease, despite a lack of clear clinical evidence demonstrating the drug's cognitive benefits.
R. Brockmann   +3 more
semanticscholar   +1 more source

Flexible Drug Approval Policies

open access: yes, 2022
Problem definition: To approve a novel drug therapy, the U.S. Food and Drug Administration (FDA) requires clinical trial evidence demonstrating efficacy with 2.5% statistical significance, although the agency often uses regulatory discretion when ...
Long, Elisa F   +2 more
core   +1 more source

Drug Approval in a Learning Health System [PDF]

open access: yes, 2018
The current system of FDA approval seems to make few happy. Some argue FDA approves drugs too slowly; others too quickly. Many agree that FDA—and the health system generally—should gather information after drugs are approved to learn how well they work ...
Nicholson Price, W., II   +1 more
core   +2 more sources

Drugs and Devices

open access: yesJACC: Basic to Translational Science, 2016
The regulation of medical drugs and devices involves competing goals of assuring safety and efficacy while providing rapid movement of innovative therapies through the investigative and regulatory processes as quickly as possible.
Gail A. Van Norman, MD
doaj   +1 more source

The drug approval tactician [PDF]

open access: yesNature Reviews Drug Discovery, 2003
Regulatory affairs in the pharmaceutical industry is both a familiar and unfamiliar world. The industry is well known as being one of the most highly regulated, revolving around the approval of new compounds that emerge from the drug development pipeline by national or multinational regulatory bodies.
openaire   +2 more sources

FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019

open access: yesJAMA Internal Medicine, 2020
This retrospective review assesses the frequency of surrogate measures used for the first time vs subsequent times in a cancer setting and the surrogate’s strength of correlation with patient-centered outcomes.
E. Chen, A. Haslam, V. Prasad
semanticscholar   +1 more source

Drugs, Devices, and the FDA: Part 1

open access: yesJACC: Basic to Translational Science, 2016
Over the last 150 years, the U.S. Food and Drug Administration (FDA) has evolved from a small division of the U.S. Patent Office to 1 of the largest consumer protection agencies in the world.
Gail A. Van Norman, MD
doaj   +1 more source

Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval

open access: yesbioRxiv, 2019
Despite strong vetting for disease activity, only 10% of candidate new molecular entities in early stage clinical trials are eventually approved. Analyzing historical pipeline data, Nelson et al. 2015 (Nat.
E. King, J. W. Davis, J. Degner
semanticscholar   +1 more source

Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US

open access: yesJAMA Network Open, 2022
Key Points Question Is drug approval by the Food and Drug Administration (FDA) associated with a reduction in disparities in novel cancer treatment use among patients with cancer in the US?
T. Ermer   +10 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy